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Methods: From a multicentric French registry (DAI-PP Registry, 2002-
2012), 5547 consecutive patients, with coronary artery disease or dilated car-
diomyopathy, were implanted with an ICD in the setting of primary preven-
tion. From 5338 (96%) patients with full information, we determined
prevalence, independent associated factors and prognosis of the occurrence of
early (within 30 days post implantation) complications. 
Results: Early complications occurred in 709 patients (13.5%), mainly
related to lead dysfunction or hematoma (56%). Independent associated fac-
tors to early complications were renal impairment (clearance <30ml/min,
OR=1.69, 95% CI 1.19-2.41, P<0.001), cardiac resynchronization therapy
(OR=1.61, 95% CI 1.17-2.21, P=0.004), anticoagulant therapy (OR=1.30,
95% CI 1.04-1.63, P=0.02) and older age (OR=1.02, 95% CI 1.01-1.02,
P=0.03). During a mean follow-up of 3.1±2.3 years, 834 patients experienced
≥1 complication (15.6%), mainly inappropriate therapies and/or lead dysfunc-
tion (75%). After consideration of potential confounding factors, early compli-
cations were significantly associated with the occurrence of late complications
(OR=2.15, 95% CI 1.73-2.66, P<0.0001) and a higher risk of overall mortality
(OR=1.48, 95% CI 1.17-1.88, P=0.001).
Conclusions: Early complication is a frequent event after ICD implantation
occurring in one out of six patients. These events are associated with a signif-
icant increase of late complications and overall mortality. 
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Few data on therapeutic management of patients over 80 years with non-
valvular atrial fibrillation (AF) are available in general population. 
Objectives: The objectives of the AF-S.AGES cohort (Sujets AGÉS) were
to describe real-life therapeutic management of non-institutionalized elderly
subjects with AF according to age groups, i.e., 65-79 and ≥80 years and to
determine factors associated with anticoagulant treatment.
Methods: General practitioners recruited 1072 patients aged ≥65 years old
between 2009 and 2011. General characteristics were first evaluated in the
overall sample and according to age groups and use of anticoagulant treatment
at inclusion. 
Results: Mean age was 78.0 (SD 6.5) years and 42% were older than
80 years. In the overall sample, 19% of patients had paroxysmal AF, 15% per-
sistent, 56% permanent and for 10% AF type was unknown. Vitamin K anta-
gonists (VKA) were used in 77% of patients, antiplatelet therapy in 17% and
12% of patients did not receive any antithrombotic treatment. There were no
differences between age-groups (< 80 or ≥80 years) for VKA (78 vs. 76%,
p=0.58). Rate control drugs were more frequently used (55%) than rhythm
control drugs (37%). Class I and class II antiarrhythmic drugs were less often
used in octogenarians than in younger patients (5.6% vs. 12.3%, p<0.001 and
36 vs. 41%, p<0.05). Among patients ≥80 years old, VKA use was associated
with permanent AF younger age and cancer. Among patients < 80 years old,
the use of VKA was associated with permanent AF and preserved functional
autonomy. HAS-BLED and HEMORR2HAGES scores were associated with
non-use of VKA in subjects ≥80 and < 80 years, CHADS2 and CHA2DS2-
VASc scores were not associated with VKA use in both groups.
Conclusions: We observed a higher use of anticoagulant therapy in elderly
AF outpatients even after 80 years when compared with previous studies.
These results suggest that recent international guidelines are better imple-
mented in the elderly population. 
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Purpose of the study: to evaluate the role of the mechanism of paroxysmal
supraventricular tachycardia (SVT) on the incidence of spontaneous atrial
fibrillation (AF). The relation between SVT and AF is well-known but its fre-
quency could depend on the mechanism of SVT.
Methods: 1559 patients, mean age 49±19 years, with SVT and without
anterograde conduction over an accessory pathway (AP) were referred for
electrophysiological study (EPS), performed in control state and after isopro-
terenol. 
Results: SVT was related to atrioventricular nodal re-entrant tachycardia
(AVNRT) in 1262 patients (group I), either typical (n=1180)(group IA) or
atypical (n=183)(group IB). In 297 patients SVT was related to atrioventric-
ular re-entrant tachycardia (AVRT) due to a concealed AP (group II). At the
initial evaluation 47 group I patients (4%)(44 of group IA, 4%, 3 of group IB,
2%), 6 of group II (2%) had presented at least one episode of sustained AF
(NS). During follow-up (mean 3±2 years), 97 patients developed AF, 86 of
group I (7%)(71 of group IA, 6%, 15 of group IB, 8%),11 of group II (4%).
AF risk was higher in group I than in group II (p<0.045); differences remain
significant for group IA/IB. When patients with AF at first study were
excluded AF risk was similar in all groups: 5% of group I)(4% of group IA;
6.5% of group IB)(0.06) and 3% of group II. Ablation of slow pathway/AP
was performed in 1099 patients, 67% of group I (69% of group IA, 51% of
group IB), 64% of group II (NS). AF risk was paradoxically higher in patients
in whom ablation was performed in group I (6.7% in group I, 7% in group IA,
13% in group IB), compared to patients without ablation (4% in group I, 4%
in group IA, 3% in group IB)(p<0.022) and was unchanged in group II (4%
after ablation and 3% in patients without ablation).
Conclusions: AF-related SVT was rare (3%), independent on the mecha-
nism of SVT. The risk of subsequent AF after a follow-up of 3 years increased
to 6% and was near 5% in patients without AF at initial evaluation; it was
only higher in patients with atypical AVNRT than in patients with AVRT. The
risk was not affected by the ablation of the slow pathway or the AP. 
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Thromboprophylaxis for patients with coronary artery disease and atrial
fibrillation (AF) is an issue when patients undergo intracoronary stent place-
ment and several recent guidelines propose slightly different management. 
Methods: All patients with AF and stent implantation seen between 2000
and 2010 in 3 academic hospitals were identified in a database and followed
up for mortality, stroke and bleeding events.
Results: Among all patients seen between 2000-2010, 343 had AF, coro-
nary stent placement and CHADS2 score=0 or 1. In these patients, OAC was
